The Workgroup for Electronic Data Interchange sent a letter to HHS Secretary Sylvia M. Burwell on March 31 explaining that the 1-year delay for implementation of the International Classification of Diseases, Tenth Revision may have done more harm than good.
The Workgroup for Electronic Data Interchange (WEDI) sent a letter to HHS Secretary Sylvia M. Burwell on March 31 explaining that the 1-year delay for implementation of the International Classification of Diseases, Tenth Revision (ICD-10) may have done more harm than good.
Based on survey responses from 1174 providers, vendors, and health plans, the delay had a negative impact on some readiness activities. While they were given more time, it appears that many organizations did not take advantage of the extra time, according to the letter.
“Unless all industry segments take the initiative to make a dedicated effort and move forward with their implementation work, there will be significant disruption on Oct. 1, 2015,” Devin Jopp, EdD, president and chief executive officer of WEDI, said in a statement.
End-to-end testing by CMS claims found 81% of ICD-10 claims received were accepted, and that the majority of rejected claims were for reasons unrelated to ICD-10. However, WEDI’s survey results tell a slightly different story.
While more than 50% of health plans have begun external testing, only a few have completed testing. In addition, only 25% of providers have begun external testing, which is actually a decrease from the 35% of respondents in the August 2014 survey.
“Based on the survey results, it appears the delay has had a negative impact on some readiness activities—especially external testing,” Jim Daley, WEDI past-chair and ICD-10 Workgroup co-chair, said. “Uncertainty over further delays was listed as a top obstacle across all industry segments.”
However, an even larger challenge was competing internal priorities, according to three-fifths of respondents. In comparison, concerns over vendor readiness, other regulatory mandates, and staffing are now less pressing.
Overall, while health plans continue to make some progress, although testing efforts have slowed, providers appear to be falling behind, according to the survey results. More than one-quarter of provider respondents said they do not expect to begin external testing until the second or third quarter of 2015, and more than one-third still does not know when they will begin testing. Plus, while three-fifths of hospitals and health systems have completed impact assessments, less than one-fifth of physician practices have done so.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More